Jack A Sargeant1,2, Stephen Bawden3,4, Guruprasad P Aithal5,4, Elizabeth J Simpson5,4, Ian A Macdonald5,4, Mark C Turner1,2, Jessica Cegielski6, Kenneth Smith6, James L Dorling1,2, Penny A Gowland3,4, Myra A Nimmo7, James A King8,9. 1. School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, LE11 3TU, UK. 2. National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK. 3. Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK. 4. National Institute of Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK. 5. Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK. 6. MRC-ARUK Centre for Musculoskeletal Ageing Research, Royal Derby Hospital Centre, University of Nottingham, Derby, UK. 7. College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK. 8. School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, LE11 3TU, UK. j.a.king@lboro.ac.uk. 9. National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK. j.a.king@lboro.ac.uk.
Abstract
PURPOSE: This study examined the feasibility of sprint interval exercise training (SIT) for men with non-alcoholic fatty liver disease (NAFLD) and its effects on intrahepatic triglyceride (IHTG), insulin sensitivity (hepatic and peripheral), visceral (VAT) and subcutaneous adipose tissue (ScAT). METHODS: Nine men with NAFLD (age 41 ± 8 years; BMI 31.7 ± 3.1 kg m-2; IHTG 15.6 ± 8.3%) were assessed at: (1) baseline (2) after a control phase of no intervention (pre-training) and (3) after 6 weeks of SIT (4-6 maximal 30 s cycling intervals, three times per week). IHTG, VAT and ScAT were measured using magnetic resonance spectroscopy or imaging and insulin sensitivity was assessed via dual-step hyperinsulinaemic-euglycaemic clamp with [6,6-D2] glucose tracer. RESULTS: Participants adhered to SIT, completing ≥ 96.7% of prescribed intervals. SIT increased peak oxygen uptake [[Formula: see text] peak: + 13.6% (95% CI 8.8-18.2%)] and elicited a relative reduction in IHTG [- 12.4% (- 31.6 to 6.7%)] and VAT [- 16.9% (- 24.4 to - 9.4%); n = 8], with no change in body weight or ScAT. Peripheral insulin sensitivity increased throughout the study (n = 8; significant main effect of phase) but changes from pre- to post-training were highly variable (range - 18.5 to + 58.7%) and not significant (P = 0.09), despite a moderate effect size (g* = 0.63). Hepatic insulin sensitivity was not influenced by SIT. CONCLUSIONS: SIT is feasible for men with NAFLD in a controlled laboratory setting and is able to reduce IHTG and VAT in the absence of weight loss.
PURPOSE: This study examined the feasibility of sprint interval exercise training (SIT) for men with non-alcoholic fatty liver disease (NAFLD) and its effects on intrahepatic triglyceride (IHTG), insulin sensitivity (hepatic and peripheral), visceral (VAT) and subcutaneous adipose tissue (ScAT). METHODS: Nine men with NAFLD (age 41 ± 8 years; BMI 31.7 ± 3.1 kg m-2; IHTG 15.6 ± 8.3%) were assessed at: (1) baseline (2) after a control phase of no intervention (pre-training) and (3) after 6 weeks of SIT (4-6 maximal 30 s cycling intervals, three times per week). IHTG, VAT and ScAT were measured using magnetic resonance spectroscopy or imaging and insulin sensitivity was assessed via dual-step hyperinsulinaemic-euglycaemic clamp with [6,6-D2] glucose tracer. RESULTS: Participants adhered to SIT, completing ≥ 96.7% of prescribed intervals. SIT increased peak oxygen uptake [[Formula: see text] peak: + 13.6% (95% CI 8.8-18.2%)] and elicited a relative reduction in IHTG [- 12.4% (- 31.6 to 6.7%)] and VAT [- 16.9% (- 24.4 to - 9.4%); n = 8], with no change in body weight or ScAT. Peripheral insulin sensitivity increased throughout the study (n = 8; significant main effect of phase) but changes from pre- to post-training were highly variable (range - 18.5 to + 58.7%) and not significant (P = 0.09), despite a moderate effect size (g* = 0.63). Hepatic insulin sensitivity was not influenced by SIT. CONCLUSIONS: SIT is feasible for men with NAFLD in a controlled laboratory setting and is able to reduce IHTG and VAT in the absence of weight loss.
Authors: Matthew Cocks; Christopher S Shaw; Sam O Shepherd; James P Fisher; Aaron Ranasinghe; Thomas A Barker; Anton J M Wagenmakers Journal: J Physiol Date: 2015-02-24 Impact factor: 5.182
Authors: Jennifer C Richards; Tyler K Johnson; Jessica N Kuzma; Mark C Lonac; Melani M Schweder; Wyatt F Voyles; Christopher Bell Journal: J Physiol Date: 2010-06-14 Impact factor: 5.182
Authors: Richard D Johnston; Mary C Stephenson; Hannah Crossland; Sally M Cordon; Elisa Palcidi; Eleanor F Cox; Moira A Taylor; Guruprasad P Aithal; Ian A Macdonald Journal: Gastroenterology Date: 2013-07-19 Impact factor: 22.682
Authors: Christopher J A Pugh; Victoria S Spring; Graham J Kemp; Paul Richardson; Fariba Shojaee-Moradie; A Margot Umpleby; Daniel J Green; N Timothy Cable; Helen Jones; Daniel J Cuthbertson Journal: Am J Physiol Heart Circ Physiol Date: 2014-11-01 Impact factor: 4.733
Authors: Haitham Abdulla; Joseph J Bass; Tanner Stokes; Stefan H M Gorissen; Chris McGlory; Bethan E Phillips; Stuart M Phillips; Kenneth Smith; Iskandar Idris; Philip J Atherton Journal: Endocrinol Diabetes Metab Date: 2019-07-26